Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : T/FIF Portfolio -- Ignore unavailable to you. Want to Upgrade?

To: scaram(o)uche who wrote (366)	1/6/1999 6:12:00 PM
From: EZLibra	Read Replies (1) \| Respond to of 1073

Hi Rick. Here's some more data to add to your antiangiogenesis folder. Maybe it should have its own folder. I've been enjoying reading your thread. -Davis. biz.yahoo.com

To: scaram(o)uche who wrote (366)	1/7/1999 11:48:00 AM
From: Arthur Radley	Read Replies (1) \| Respond to of 1073

A question has been raised about GLGC. This is a stock that I have a position in and would like to open a dialog about the future of this company and what it has(IMO)to offer the major drug companies. Gene Logic is a genomics and bioinformatics company that in only two years of existence, has created a nice association with many of the major drug companies...American Home, Merck, Proctor and Gamble, SmithKline, Rhone-Poulenc, and Japan Tobacco(Hell of name for a drug company). This is just a partial list of the nine companies that they have contracts with at the current time. What I think might be a unique feature of this company is the Data Logic division, based in Berkeley, CA. They develop and market advanced bioformatics software for managing and integrating genomic data. I would welcome any input from others as to the merits of GLGC. I would suggest everyone read the recent interview given by Michael Brennan, CEO, to The Wall Street Transcript. I think this is available at the news section for GLGC, here on SI.